Tran et al. 2018

Quick Summary

This research paper describes the discovery of a "new" genetic condition caused by changes in the *IRF2BPL* gene. For many years, the cause of certain types of childhood neurological regression—where a child gains skills normally but then begins to lose them—remained a mystery. By using advanced genetic testing called exome sequencing, an international team of scientists identified 11 unrelated individuals who all shared very similar symptoms and had similar "misspellings" in the same gene.

The study found that children with this condition typically have a normal start in life. They hit their early milestones like sitting up, walking, and saying their first words on time. However, usually between the ages of 1 and 7, they begin to experience a "regression." This means they might lose the ability to walk, speak, or coordinate their movements. Many also develop epilepsy (seizures) that can be very difficult to control with standard medications.

By comparing the genetic data of these 11 families, the researchers proved that these specific genetic changes were "de novo," meaning they happened by chance in the child and were not inherited from the parents. This paper was one of the very first to define this condition (now often called NEDAMSS) and provides a roadmap for doctors to help diagnose other children who have similar symptoms.

Why This Paper Matters

This article is a foundational piece of the *IRF2BPL* story. Before this study, the *IRF2BPL* gene (also known as *EAP1*) was mostly studied in relation to how the body triggers puberty. This paper shifted the entire scientific focus by showing that this gene is actually critical for maintaining the health of brain cells throughout childhood and adulthood.

It is important because it gave a name and a cause to a condition that had previously left families without answers. It also highlighted a specific pattern—normal early development followed by later loss of skills—that helps doctors distinguish this condition from other disorders like Rett Syndrome or Angelman Syndrome. By identifying the exact "missing piece" in the protein (the RING-finger domain), the researchers gave scientists a target for future studies on potential treatments.

What The Researchers Studied

The researchers conducted a primary cohort study involving 11 unrelated individuals from different parts of the world. The study began when one boy was found to have a unique genetic variant through "trio-based exome sequencing"—a process where the DNA of the child and both biological parents is analyzed simultaneously to find new changes.

To find more people with the same condition, the scientists used an international "matching" tool called GeneMatcher. This allowed them to connect with other doctors and researchers who had patients with similar symptoms and the same genetic "hit."

The data used in the study included:

* Detailed medical histories and developmental milestones. * Results from MRI scans of the brain. * EEG (brain wave) recordings to study seizure activity. * Genetic sequencing data to locate the specific "misspellings" in the *IRF2BPL* gene. * Muscle biopsies and skin cell (fibroblast) studies to see how the genetic change affected the body's cells.

What Was Learned About Symptoms

The researchers noted a very consistent set of symptoms across the 11 patients, though the severity varied from person to person.

Development and Regression

The hallmark of this condition was "secondary global neurological regression."

* Early Stages: 7 out of 11 children had completely normal motor development at the start. Most sat and walked at typical ages. * The Turn: Regression typically started early in childhood, with a mean age of 6 years (though it ranged from 1 to 17 years). * Loss of Skills: Children often lost the ability to walk and speak. Those who experienced regression earlier in life tended to have more severe outcomes.

Seizures and Brain Activity

Epilepsy was a major feature, affecting 7 of the 11 patients.

* Types: Seizures included infantile spasms, myoclonus (brief, involuntary muscle jerks), and tonic-clonic seizures. * Treatment: The seizures were often "intractable," meaning they did not respond well to medications. Only 2 of the 8 patients with epilepsy showed a good response to treatment. * EEG: Brain wave tests often showed "nonspecific" abnormalities, meaning the patterns were clearly irregular but didn't point to one specific type of epilepsy.

Movement and Physical Symptoms

As the condition progressed, many children developed movement disorders:

* Ataxia: Difficulty with coordination and balance. * Dystonia: Involuntary muscle contractions that cause repetitive or twisting movements. * Hypotonia: Low muscle tone (feeling "floppy"). * Tetraparesis: Weakness affecting all four limbs.

Brain Imaging (MRI)

In about 60% of the cases, MRI scans showed that the brain was shrinking (atrophy). This was seen in both the main part of the brain (cerebrum) and the part responsible for balance (cerebellum). Importantly, the "white matter" of the brain usually looked normal, which helps doctors rule out other specific brain diseases.

What Was Learned About Genetics

The study focused on a specific type of genetic change called a truncating variant.

In our DNA, genes act like instruction manuals for building proteins. A truncating variant is like a "stop" command placed in the middle of a sentence. Because of this, the cell creates a protein that is shorter than it should be.

Key genetic findings included:

* De Novo Changes: All identified variants were "de novo," meaning they were not passed down from the parents but occurred spontaneously. * Location: The *IRF2BPL* gene is "intronless," which is rare. Usually, when a gene has a "stop" command in the wrong place, the cell destroys the broken instruction (a process called NMD). However, because this gene is intronless, it "escapes" that destruction. This means the cell actually goes ahead and builds the shortened, broken protein. * The Missing Piece: All the variants identified in the study resulted in a protein that was missing its "tail"—a section called the C-terminal RING-finger domain. * The Role of the Tail: This missing section is normally used by the cell to recycle other proteins. Without it, the *IRF2BPL* protein cannot do its job as a "transcriptional regulator" (a master switch that turns other genes on or off).

Patient And Cohort Details

The 11 patients (5 males, 6 females) ranged in age from 2 years to 48 years at the time of the study.

* Group 1 (Typical Course): Most patients (9 out of 11) followed the pattern of normal or near-normal early development followed by regression. For example, Patient 1 walked at 15 months but began losing skills around age 5. * Group 2 (Late Onset): Two patients (Patients 3 and 4) did not start regressing until they were 10 and 17 years old. They had a less severe course and were still able to walk in their 20s. * Group 3 (Early/Severe): Two patients (Patients 7 and 11) had a much more severe start, with seizures beginning as early as 2.5 months old and never achieving the ability to sit or walk. * Current Status: At the time of the report, the oldest patient was 48 years old, illustrating that while the condition is progressive and severe, individuals can live into adulthood with appropriate care.

What Families Can Take Away

1. Diagnosis is the First Step: If a child is experiencing unexplained loss of skills, exome sequencing for the *IRF2BPL* gene is a vital tool for finding an answer. 1. Every Child is Unique: The study shows a "spectrum." Some children have symptoms very early, while others don't show signs of regression until their teens. Clinical decisions should always be made with your specific medical team. 1. Seizure Management: Epilepsy in this condition can be tough to treat. Families should work closely with a pediatric neurologist to find the best combination of therapies. 1. Multidisciplinary Care: Because the symptoms affect movement, speech, swallowing, and brain health, families often benefit from a team that includes neurologists, physical therapists, and speech-language pathologists.

Limits Of The Paper

While this study is a breakthrough, it has some limitations:

* Small Sample Size: With only 11 patients, it is hard to predict exactly how the condition will progress for every person. * Retrospective: Much of the data was gathered by looking back at old medical records, which might not have every detail recorded consistently. * No Standardized Testing: The researchers could not perform formal IQ tests on all patients because of the severity of the regression, making it hard to track exact cognitive changes. * No Treatment Cure: The paper identifies the cause of the disease but does not provide a cure or a specific "best" medication, as this was not the goal of the study.

Source Notes

This summary is based on the following sections of the article "De novo truncating variants in the intronless IRF2BPL are responsible for developmental epileptic encephalopathy":

* Results Section: Details on the 11 patients and the identification of the variants. * Table 1: Comprehensive clinical, EEG, and radiological features of all 11 patients. * Discussion Section: Comparison of *IRF2BPL* symptoms with Rett and Angelman syndromes. * Figure 1: MRI images of brain atrophy and the diagram of the protein structure. * Introduction: Background on the definition of Developmental and Epileptic Encephalopathy (DEE).